Sjöström J, Krajewski S, Franssila K, Niskanen E, Wasenius V M, Nordling S, Reed J C, Blomqvist C
Department of Oncology, Helsinki University Central Hospital, Finland.
Br J Cancer. 1998 Sep;78(6):812-5. doi: 10.1038/bjc.1998.584.
The study was designed to identify factors that could predict response to chemotherapy in breast cancer. A total of 173 patients with measurable or evaluable metastatic breast cancer were enrolled in a randomized trial between November 1987 and January 1991 to receive a monthly dose of 5-fluorouracil (500 mg m(-2)), epirubicin (60 mg m(-2)) and cyclophosphamide (500 mg m(-2)) either administered in four weekly doses or in an every-4-week dose as first-line cytotoxic treatment. In 103 evaluable patients we performed a multivariate analysis of the tumour biological factors, i.e. histological grade, oestrogen receptor (ER), progesterone receptor (PR), S-phase fraction (SPF), ploidy, p53, c-erbB-2, Bcl-2 and Bax expression, which showed significance in the univariate analysis according to treatment response, time to progression (TTP) or overall survival (OS). In the univariate analysis only SPF, grade and the proapoptotic protein Bax correlated with the response to cytotoxic treatment. In the multivariate analysis SPF had the strongest correlation, followed by grade and Bax. In the univariate analysis grade, PR, Bax and Bcl-2 correlated significantly with TTP, whereas in the multivariate analysis only PR showed a statistically significant correlation. In the univariate analysis PR and Bax correlated with OS and both retained its significance in the multivariate analysis. The factors that correlated significantly with the response to cytotoxic treatment in the univariate analysis, i.e. grade, SPF and Bax, seemed to predict independently the response to treatment in the multivariate analysis also. TTP and OS could be predicted partly by the same factors, although the association was quite weak. More studies and new tumour biological factors are needed to identify the group of breast cancer patients who get the most benefit from chemotherapy.
该研究旨在确定可预测乳腺癌化疗反应的因素。1987年11月至1991年1月期间,共有173例可测量或可评估的转移性乳腺癌患者参加了一项随机试验,接受每月剂量的5-氟尿嘧啶(500 mg m(-2))、表柔比星(60 mg m(-2))和环磷酰胺(500 mg m(-2)),以四周一次剂量或每4周一次剂量给药,作为一线细胞毒性治疗。在103例可评估患者中,我们对肿瘤生物学因素进行了多变量分析,即组织学分级、雌激素受体(ER)、孕激素受体(PR)、S期分数(SPF)、倍性、p53、c-erbB-2、Bcl-2和Bax表达,这些因素在单变量分析中根据治疗反应、疾病进展时间(TTP)或总生存期(OS)显示出显著性。在单变量分析中,只有SPF、分级和促凋亡蛋白Bax与细胞毒性治疗反应相关。在多变量分析中,SPF的相关性最强,其次是分级和Bax。在单变量分析中,分级、PR、Bax和Bcl-2与TTP显著相关,而在多变量分析中只有PR显示出统计学上的显著相关性。在单变量分析中,PR和Bax与OS相关,且两者在多变量分析中均保持其显著性。在单变量分析中与细胞毒性治疗反应显著相关的因素,即分级、SPF和Bax,在多变量分析中似乎也能独立预测治疗反应。TTP和OS可部分由相同因素预测,尽管这种关联相当微弱。需要更多的研究和新的肿瘤生物学因素来确定从化疗中获益最大的乳腺癌患者群体。